Kadcyla from Roche and ImmunoGen wins FDA thumbs up ROG & IMGN

Boston, MA 02/25/2013 (wallstreetpr) – Roche Holding Ltd (VTX: ROG) in partnership with ImmunoGen, Inc (NASDAQ:IMGN has created an anti-cancer therapy that has gained approval from the U.S Food Drug Administration. The drug which was originally called T-DM1 will now be sold under the brand name Kadcyla as it has received clearance for treating humans who suffer from Her2(positive metastatic breast cancer). The therapy is a combination of the anti-cancer drug manufactured by Roche Holding Ltd (VTX: ROG) and technology from ImmunoGen, Inc (NASDAQ:IMGN)’s.

Killing cancer cells and boosting company growth

This therapy ensures that the drug bypasses healthy cells and carries the chemotherapy straight to the malignant ones. ImmunoGen, Inc (NASDAQ:IMGN) announced that its U.S approval will earn it $10.5 million. According to a market analyst, this high-potential drug is expected to generate over $5 billion of worldwide sales. Sandra Horning, head of global oncology at the Switzerland-based Roche Holding Ltd (VTX: ROG) said that the therapy is a super-Herceptin of sorts. Another important plus is that the drug has fewer side-effects when compared to other existing therapies.

Herceptin before Kadcyla

Kadcyla will be launched in the U.S within a fortnight but the FDA has said that patients should first try Herceptin treatment before moving onto Kadcyla, both of which are  Roche Holding Ltd (VTX:ROG) products. The cost of the Kadcyla treatment will amount to $9800 per month and will have to continue for 9.6 months taking its cost to $94,000 for the entire course. Roche Holding Ltd (VTX: ROG), the worlds largest manufacturer of tumor medication is testing the same drug as a first-line treatment for women who suffer from spreading (metastatic) breast cancer. ImmunoGen, Inc (NASDAQ:IMGN) will be receiving between 3 percent- 7 percent in royalties and its worldwide collections from royalties could be to the tune of $350 million by 2025. T-DM1 prevents the growth of new cancer cells and the DM1 release destroys them and the approval of this drug has opened up a host of possibilities in the treatment of cancer.

Shares of ImmunoGen, Inc (NASDAQ:IMGN) went up by 1.89% to close at $14.57

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Van Bettauer

Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https://plus.google.com/100770875710593766367/posts